Pre‐treatments enhance the therapeutic effects of mesenchymal stem cells in liver diseases
Liver diseases caused by viral infection, alcohol abuse and metabolic disorders can progress to end‐stage liver failure, liver cirrhosis and liver cancer, which are a growing cause of death worldwide. Although liver transplantation and hepatocyte transplantation are useful strategies to promote live...
Gespeichert in:
| Veröffentlicht in: | Journal of cellular and molecular medicine 2020-01, Vol.24 (1), p.40-49 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 49 |
|---|---|
| container_issue | 1 |
| container_start_page | 40 |
| container_title | Journal of cellular and molecular medicine |
| container_volume | 24 |
| creator | Hu, Chenxia Wu, Zhongwen Li, Lanjuan |
| description | Liver diseases caused by viral infection, alcohol abuse and metabolic disorders can progress to end‐stage liver failure, liver cirrhosis and liver cancer, which are a growing cause of death worldwide. Although liver transplantation and hepatocyte transplantation are useful strategies to promote liver regeneration, they are limited by scarce sources of organs and hepatocytes. Mesenchymal stem cells (MSCs) restore liver injury after hepatogenic differentiation and exert immunomodulatory, anti‐inflammatory, antifibrotic, antioxidative stress and antiapoptotic effects on liver cells in vivo. After isolation and culture in vitro, MSCs are faced with nutrient and oxygen deprivation, and external growth factors maintain MSC capacities for further applications. In addition, MSCs are placed in a harsh microenvironment, and anoikis and inflammation after transplantation in vivo significantly decrease their regenerative capacity. Pre‐treatment with chemical agents, hypoxia, an inflammatory microenvironment and gene modification can protect MSCs against injury, and pre‐treated MSCs show improved hepatogenic differentiation, homing capacity, survival and paracrine effects in vitro and in vivo in regard to attenuating liver injury. In this review, we mainly focus on pre‐treatments and the underlying mechanisms for improving the therapeutic effects of MSCs in various liver diseases. Thus, we provide evidence for the development of MSC‐based cell therapy to prevent acute or chronic liver injury. Mesenchymal stem cells have potential as a therapeutic to prolong the survival of patients with end‐stage liver diseases in the near future. |
| doi_str_mv | 10.1111/jcmm.14788 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6933358</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2312548554</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5428-9791ed37087d7d76e7f5a3be80f2099ee934725f0cfe63e968a97b47fe81a8e33</originalsourceid><addsrcrecordid>eNp9kc1qVDEYhoMotlY3XoAE3EhhanK-5CTZCGWw_tCiC90JIZP54mQ4OWdMzqnMzkvwGr0SM52xqIsmhAS-h4e8vIQ85eyM1_Vy7VM640JpfY8cc6mbmTAg7h_eXIM-Io9KWTMGLQfzkBwBbw0XLRyTLx8z_vrxc8zoxoT9WCj2K9d7pOPq5mS3wWmMnmII6Ot8CDRhwd6vtsl1tIyYqMeuKzT2tIvXmOkyFnQFy2PyILiu4JPDfUI-X7z-NH87u_zw5t38_HLmpWj0zCjDcQmKabWsu0UVpIMFahYaZgxiTaMaGZgP2AKaVjujFkIF1NxpBDghr_bezbRIuPQ1R3ad3eSYXN7awUX776SPK_t1uLatAQCpq-DFQZCHbxOW0aZYdqFcj8NUbAO8kUJLKSr6_D90PUy5r_FsIxuptQCh76QAmKo-rSp1uqd8HkrJGG6_zJndVWt31dqbaiv87O-Qt-ifLivA98D32OH2DpV9P7-62kt_A-FAsDg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2330731287</pqid></control><display><type>article</type><title>Pre‐treatments enhance the therapeutic effects of mesenchymal stem cells in liver diseases</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Hu, Chenxia ; Wu, Zhongwen ; Li, Lanjuan</creator><creatorcontrib>Hu, Chenxia ; Wu, Zhongwen ; Li, Lanjuan</creatorcontrib><description>Liver diseases caused by viral infection, alcohol abuse and metabolic disorders can progress to end‐stage liver failure, liver cirrhosis and liver cancer, which are a growing cause of death worldwide. Although liver transplantation and hepatocyte transplantation are useful strategies to promote liver regeneration, they are limited by scarce sources of organs and hepatocytes. Mesenchymal stem cells (MSCs) restore liver injury after hepatogenic differentiation and exert immunomodulatory, anti‐inflammatory, antifibrotic, antioxidative stress and antiapoptotic effects on liver cells in vivo. After isolation and culture in vitro, MSCs are faced with nutrient and oxygen deprivation, and external growth factors maintain MSC capacities for further applications. In addition, MSCs are placed in a harsh microenvironment, and anoikis and inflammation after transplantation in vivo significantly decrease their regenerative capacity. Pre‐treatment with chemical agents, hypoxia, an inflammatory microenvironment and gene modification can protect MSCs against injury, and pre‐treated MSCs show improved hepatogenic differentiation, homing capacity, survival and paracrine effects in vitro and in vivo in regard to attenuating liver injury. In this review, we mainly focus on pre‐treatments and the underlying mechanisms for improving the therapeutic effects of MSCs in various liver diseases. Thus, we provide evidence for the development of MSC‐based cell therapy to prevent acute or chronic liver injury. Mesenchymal stem cells have potential as a therapeutic to prolong the survival of patients with end‐stage liver diseases in the near future.</description><identifier>ISSN: 1582-1838</identifier><identifier>EISSN: 1582-4934</identifier><identifier>DOI: 10.1111/jcmm.14788</identifier><identifier>PMID: 31691463</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Abuse ; Alcohol abuse ; Analgesics ; Animals ; Anoikis ; Anti-Inflammatory Agents - pharmacology ; Apoptosis ; Bile ; Cell culture ; Cell Differentiation ; Cell Hypoxia ; Cell therapy ; Chemical agents ; Cirrhosis ; Collagen ; Cytokeratin ; Cytokines ; Drug abuse ; Fibroblasts ; gene modification ; Genetic modification ; Growth factors ; Hepatitis ; Hepatocytes ; Homing ; Humans ; Hypoxia ; Immunomodulation ; Inflammation ; Kinases ; Liver ; Liver cancer ; Liver cirrhosis ; liver disease ; Liver diseases ; Liver Diseases - pathology ; Liver Diseases - therapy ; Liver Regeneration ; Liver transplantation ; Medical prognosis ; mesenchymal stem cell ; Mesenchymal Stem Cell Transplantation - methods ; Mesenchymal stem cells ; Mesenchymal Stem Cells - cytology ; Mesenchymal Stem Cells - drug effects ; Mesenchyme ; Metabolic disorders ; Metabolism ; Metastasis ; Microenvironments ; Organs ; Oxidative stress ; Paracrine signalling ; pre‐treatment ; Proteins ; Review ; Reviews ; Stem cells ; Surgical outcomes ; Survival ; Transplantation ; Transplantation Conditioning ; Tumor necrosis factor-TNF</subject><ispartof>Journal of cellular and molecular medicine, 2020-01, Vol.24 (1), p.40-49</ispartof><rights>2019 The Authors. published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.</rights><rights>2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5428-9791ed37087d7d76e7f5a3be80f2099ee934725f0cfe63e968a97b47fe81a8e33</citedby><cites>FETCH-LOGICAL-c5428-9791ed37087d7d76e7f5a3be80f2099ee934725f0cfe63e968a97b47fe81a8e33</cites><orcidid>0000-0001-6945-0593</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933358/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933358/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31691463$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hu, Chenxia</creatorcontrib><creatorcontrib>Wu, Zhongwen</creatorcontrib><creatorcontrib>Li, Lanjuan</creatorcontrib><title>Pre‐treatments enhance the therapeutic effects of mesenchymal stem cells in liver diseases</title><title>Journal of cellular and molecular medicine</title><addtitle>J Cell Mol Med</addtitle><description>Liver diseases caused by viral infection, alcohol abuse and metabolic disorders can progress to end‐stage liver failure, liver cirrhosis and liver cancer, which are a growing cause of death worldwide. Although liver transplantation and hepatocyte transplantation are useful strategies to promote liver regeneration, they are limited by scarce sources of organs and hepatocytes. Mesenchymal stem cells (MSCs) restore liver injury after hepatogenic differentiation and exert immunomodulatory, anti‐inflammatory, antifibrotic, antioxidative stress and antiapoptotic effects on liver cells in vivo. After isolation and culture in vitro, MSCs are faced with nutrient and oxygen deprivation, and external growth factors maintain MSC capacities for further applications. In addition, MSCs are placed in a harsh microenvironment, and anoikis and inflammation after transplantation in vivo significantly decrease their regenerative capacity. Pre‐treatment with chemical agents, hypoxia, an inflammatory microenvironment and gene modification can protect MSCs against injury, and pre‐treated MSCs show improved hepatogenic differentiation, homing capacity, survival and paracrine effects in vitro and in vivo in regard to attenuating liver injury. In this review, we mainly focus on pre‐treatments and the underlying mechanisms for improving the therapeutic effects of MSCs in various liver diseases. Thus, we provide evidence for the development of MSC‐based cell therapy to prevent acute or chronic liver injury. Mesenchymal stem cells have potential as a therapeutic to prolong the survival of patients with end‐stage liver diseases in the near future.</description><subject>Abuse</subject><subject>Alcohol abuse</subject><subject>Analgesics</subject><subject>Animals</subject><subject>Anoikis</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Apoptosis</subject><subject>Bile</subject><subject>Cell culture</subject><subject>Cell Differentiation</subject><subject>Cell Hypoxia</subject><subject>Cell therapy</subject><subject>Chemical agents</subject><subject>Cirrhosis</subject><subject>Collagen</subject><subject>Cytokeratin</subject><subject>Cytokines</subject><subject>Drug abuse</subject><subject>Fibroblasts</subject><subject>gene modification</subject><subject>Genetic modification</subject><subject>Growth factors</subject><subject>Hepatitis</subject><subject>Hepatocytes</subject><subject>Homing</subject><subject>Humans</subject><subject>Hypoxia</subject><subject>Immunomodulation</subject><subject>Inflammation</subject><subject>Kinases</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>liver disease</subject><subject>Liver diseases</subject><subject>Liver Diseases - pathology</subject><subject>Liver Diseases - therapy</subject><subject>Liver Regeneration</subject><subject>Liver transplantation</subject><subject>Medical prognosis</subject><subject>mesenchymal stem cell</subject><subject>Mesenchymal Stem Cell Transplantation - methods</subject><subject>Mesenchymal stem cells</subject><subject>Mesenchymal Stem Cells - cytology</subject><subject>Mesenchymal Stem Cells - drug effects</subject><subject>Mesenchyme</subject><subject>Metabolic disorders</subject><subject>Metabolism</subject><subject>Metastasis</subject><subject>Microenvironments</subject><subject>Organs</subject><subject>Oxidative stress</subject><subject>Paracrine signalling</subject><subject>pre‐treatment</subject><subject>Proteins</subject><subject>Review</subject><subject>Reviews</subject><subject>Stem cells</subject><subject>Surgical outcomes</subject><subject>Survival</subject><subject>Transplantation</subject><subject>Transplantation Conditioning</subject><subject>Tumor necrosis factor-TNF</subject><issn>1582-1838</issn><issn>1582-4934</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kc1qVDEYhoMotlY3XoAE3EhhanK-5CTZCGWw_tCiC90JIZP54mQ4OWdMzqnMzkvwGr0SM52xqIsmhAS-h4e8vIQ85eyM1_Vy7VM640JpfY8cc6mbmTAg7h_eXIM-Io9KWTMGLQfzkBwBbw0XLRyTLx8z_vrxc8zoxoT9WCj2K9d7pOPq5mS3wWmMnmII6Ot8CDRhwd6vtsl1tIyYqMeuKzT2tIvXmOkyFnQFy2PyILiu4JPDfUI-X7z-NH87u_zw5t38_HLmpWj0zCjDcQmKabWsu0UVpIMFahYaZgxiTaMaGZgP2AKaVjujFkIF1NxpBDghr_bezbRIuPQ1R3ad3eSYXN7awUX776SPK_t1uLatAQCpq-DFQZCHbxOW0aZYdqFcj8NUbAO8kUJLKSr6_D90PUy5r_FsIxuptQCh76QAmKo-rSp1uqd8HkrJGG6_zJndVWt31dqbaiv87O-Qt-ifLivA98D32OH2DpV9P7-62kt_A-FAsDg</recordid><startdate>202001</startdate><enddate>202001</enddate><creator>Hu, Chenxia</creator><creator>Wu, Zhongwen</creator><creator>Li, Lanjuan</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6945-0593</orcidid></search><sort><creationdate>202001</creationdate><title>Pre‐treatments enhance the therapeutic effects of mesenchymal stem cells in liver diseases</title><author>Hu, Chenxia ; Wu, Zhongwen ; Li, Lanjuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5428-9791ed37087d7d76e7f5a3be80f2099ee934725f0cfe63e968a97b47fe81a8e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Abuse</topic><topic>Alcohol abuse</topic><topic>Analgesics</topic><topic>Animals</topic><topic>Anoikis</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Apoptosis</topic><topic>Bile</topic><topic>Cell culture</topic><topic>Cell Differentiation</topic><topic>Cell Hypoxia</topic><topic>Cell therapy</topic><topic>Chemical agents</topic><topic>Cirrhosis</topic><topic>Collagen</topic><topic>Cytokeratin</topic><topic>Cytokines</topic><topic>Drug abuse</topic><topic>Fibroblasts</topic><topic>gene modification</topic><topic>Genetic modification</topic><topic>Growth factors</topic><topic>Hepatitis</topic><topic>Hepatocytes</topic><topic>Homing</topic><topic>Humans</topic><topic>Hypoxia</topic><topic>Immunomodulation</topic><topic>Inflammation</topic><topic>Kinases</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>liver disease</topic><topic>Liver diseases</topic><topic>Liver Diseases - pathology</topic><topic>Liver Diseases - therapy</topic><topic>Liver Regeneration</topic><topic>Liver transplantation</topic><topic>Medical prognosis</topic><topic>mesenchymal stem cell</topic><topic>Mesenchymal Stem Cell Transplantation - methods</topic><topic>Mesenchymal stem cells</topic><topic>Mesenchymal Stem Cells - cytology</topic><topic>Mesenchymal Stem Cells - drug effects</topic><topic>Mesenchyme</topic><topic>Metabolic disorders</topic><topic>Metabolism</topic><topic>Metastasis</topic><topic>Microenvironments</topic><topic>Organs</topic><topic>Oxidative stress</topic><topic>Paracrine signalling</topic><topic>pre‐treatment</topic><topic>Proteins</topic><topic>Review</topic><topic>Reviews</topic><topic>Stem cells</topic><topic>Surgical outcomes</topic><topic>Survival</topic><topic>Transplantation</topic><topic>Transplantation Conditioning</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hu, Chenxia</creatorcontrib><creatorcontrib>Wu, Zhongwen</creatorcontrib><creatorcontrib>Li, Lanjuan</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cellular and molecular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hu, Chenxia</au><au>Wu, Zhongwen</au><au>Li, Lanjuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pre‐treatments enhance the therapeutic effects of mesenchymal stem cells in liver diseases</atitle><jtitle>Journal of cellular and molecular medicine</jtitle><addtitle>J Cell Mol Med</addtitle><date>2020-01</date><risdate>2020</risdate><volume>24</volume><issue>1</issue><spage>40</spage><epage>49</epage><pages>40-49</pages><issn>1582-1838</issn><eissn>1582-4934</eissn><abstract>Liver diseases caused by viral infection, alcohol abuse and metabolic disorders can progress to end‐stage liver failure, liver cirrhosis and liver cancer, which are a growing cause of death worldwide. Although liver transplantation and hepatocyte transplantation are useful strategies to promote liver regeneration, they are limited by scarce sources of organs and hepatocytes. Mesenchymal stem cells (MSCs) restore liver injury after hepatogenic differentiation and exert immunomodulatory, anti‐inflammatory, antifibrotic, antioxidative stress and antiapoptotic effects on liver cells in vivo. After isolation and culture in vitro, MSCs are faced with nutrient and oxygen deprivation, and external growth factors maintain MSC capacities for further applications. In addition, MSCs are placed in a harsh microenvironment, and anoikis and inflammation after transplantation in vivo significantly decrease their regenerative capacity. Pre‐treatment with chemical agents, hypoxia, an inflammatory microenvironment and gene modification can protect MSCs against injury, and pre‐treated MSCs show improved hepatogenic differentiation, homing capacity, survival and paracrine effects in vitro and in vivo in regard to attenuating liver injury. In this review, we mainly focus on pre‐treatments and the underlying mechanisms for improving the therapeutic effects of MSCs in various liver diseases. Thus, we provide evidence for the development of MSC‐based cell therapy to prevent acute or chronic liver injury. Mesenchymal stem cells have potential as a therapeutic to prolong the survival of patients with end‐stage liver diseases in the near future.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>31691463</pmid><doi>10.1111/jcmm.14788</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-6945-0593</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1582-1838 |
| ispartof | Journal of cellular and molecular medicine, 2020-01, Vol.24 (1), p.40-49 |
| issn | 1582-1838 1582-4934 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6933358 |
| source | MEDLINE; Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Abuse Alcohol abuse Analgesics Animals Anoikis Anti-Inflammatory Agents - pharmacology Apoptosis Bile Cell culture Cell Differentiation Cell Hypoxia Cell therapy Chemical agents Cirrhosis Collagen Cytokeratin Cytokines Drug abuse Fibroblasts gene modification Genetic modification Growth factors Hepatitis Hepatocytes Homing Humans Hypoxia Immunomodulation Inflammation Kinases Liver Liver cancer Liver cirrhosis liver disease Liver diseases Liver Diseases - pathology Liver Diseases - therapy Liver Regeneration Liver transplantation Medical prognosis mesenchymal stem cell Mesenchymal Stem Cell Transplantation - methods Mesenchymal stem cells Mesenchymal Stem Cells - cytology Mesenchymal Stem Cells - drug effects Mesenchyme Metabolic disorders Metabolism Metastasis Microenvironments Organs Oxidative stress Paracrine signalling pre‐treatment Proteins Review Reviews Stem cells Surgical outcomes Survival Transplantation Transplantation Conditioning Tumor necrosis factor-TNF |
| title | Pre‐treatments enhance the therapeutic effects of mesenchymal stem cells in liver diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T17%3A43%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pre%E2%80%90treatments%20enhance%20the%20therapeutic%20effects%20of%20mesenchymal%20stem%20cells%20in%20liver%20diseases&rft.jtitle=Journal%20of%20cellular%20and%20molecular%20medicine&rft.au=Hu,%20Chenxia&rft.date=2020-01&rft.volume=24&rft.issue=1&rft.spage=40&rft.epage=49&rft.pages=40-49&rft.issn=1582-1838&rft.eissn=1582-4934&rft_id=info:doi/10.1111/jcmm.14788&rft_dat=%3Cproquest_pubme%3E2312548554%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2330731287&rft_id=info:pmid/31691463&rfr_iscdi=true |